On the stock market since 2019, it operates in the world of health and science. It has 510 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 49% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 87% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 53% a year on average.
Sales run at $268.8M a year. A small number, but proof the product has real buyers.
Over the last 12 months, company executives reported 18 buys and 12 sells. Management buying with its own money is usually read as a good sign.
A loss of $68.1M against $268.8M in annual sales.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
The stock trades 95% above the average analyst price target.
On our five-subject report card, VREOF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: VREOF is a high-risk stock — not yet profitable, and its future rides on its product catching on.